CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Eltrombopagdrug
Likely dose
Eltrombopag 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01168921
NCT01168921Phase 2Completed
CompareCT.gov

A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

M.D. Anderson Cancer Center·interventional·Posted Jul 23, 2010·Updated Mar 23, 2023

In Brief

A Phase 2 clinical trial evaluating Eltrombopag for CLL and Leukemia. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if eltrombopag can help to increase the number of platelets in patients with CLL. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCLL, Leukemia
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 23, 2010
Enrollment StartNov 3, 2010
Primary CompletionMar 7, 2022
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 15.9 years ago

Interventions

Eltrombopagdrug

Starting dose 75 mg by mouth (PO) daily for 28 day cycle